Cambridge Innovation Capital plc (CIC) combines a unique relationship with the University of Cambridge with deep financial and industry links to invest in rapidly growing intellectual property rich companies in the Cambridge Cluster. CIC has an unrivalled appreciation for the application of world-leading scientific developments given its position within the Cambridge Cluster. The company is committed to building leading businesses from brilliant technologies – with the support of some of the most influential figures in the sector and a patient capital structure. For further information, including more details of CIC portfolio companies, see: www.cicplc.co.uk
M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck’s science and technology base. Find out more at: www.m-ventures.com
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer Inc, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of worldwide business development, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry. Find out more here.
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co. Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is looking at early stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review the wide variety of modalities for both biologics and small molecules mainly in US and European countries. The company will also consider the option-type of investments and spin-outs, in addition to the pure equity investments. See http://www.taihoventures.com/
Find out more about our: